



165 – 10551 Shellbridge Way  
Richmond, BC, V6X 2W8

## **BIOMARK RECORDS FIRST REVENUES**

Vancouver, British Columbia – (December 4, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) is pleased to announce that it has recorded its first revenue for its 1<sup>st</sup> generation, state-of-the-art Surface Enhance Raman Spectrometer (SERS) technology.

Raman Spectrometry, enhances with the BioMark’s patented use of amantadine for cancer diagnostics, will once successful trials are complete and approvals are granted, enable the low cost early detection of cancer.

This first sale of BioMark’s Raman technology is a validation of the direct investment that has been made in projects associated with SERS and is an acknowledgement that one of the technical platforms to be used in detecting small molecules, such as acetylated amantadine, is market ready. The SERS technology not only can be used to detect acetylated amantadine, but it can also be used in other biophotonic and metabolomic applications, which have global applications in the health and medical sectors.

President and CEO, Rashid Ahmed says, “We are very pleased and grateful for the hard work by BioMark’s own scientific and technical team along with leading academic and research institutions in Canada and US-based Innovative Photonic Solutions We are proud that the first of its kind portable SERS was launched at the inaugural Strategies in Biophotonics conference, which was held in Boston in September 2014 and attended by leading scientists. I look forward to further collaboration as the company moves forward in commercialization of the current generation technology and looking at future development of paper-SERS technology that will potentially have broad-based global biophotonic and metabolomics applications.”

### **About BioMark Diagnostics Inc.**

BioMark currently has an expanded multi-site Phase 3 Clinical trial underway in Canada and Bangladesh evaluating its early-stage cancer protocols. This technology, which is proprietary, patented and non-invasive, will potentially provide accurate and low cost cancer diagnosis. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website [www.sedar.com](http://www.sedar.com) and on the CSE website [www.thecse.ca](http://www.thecse.ca).

**For further information on BioMark, please Contact:**

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

**The CSE has not reviewed, approved or disapproved the content of this press release.**